The multidisciplinary DIABAT approach integrates recent technological and conceptual advances developed by the scientific and industrial participants, including functional genomic insights into BAT biology as well as in-patient trials to overall develop innovative, energy-consuming, BAT-centered therapies for at-risk individuals and patients with type 2 diabetes.

DIABAT addresses the topic HEALTH-2011-2.4.3-2: “Development of novel treatment strategies based on knowledge of cellular dysfunction”. DIABAT brings together universities, research institutions, a large biotechnological company and 2 SMEs to employ knowledge of the function, dysfunction and physiological regulation of brown adipocytes to develop innovative therapeutic and preventive strategies for type 2 diabetes.

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under Grant agreement number HEALTH-F2-2011-278373.